TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

Telix Pharmaceuticals Limited, today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent ...

The quest for more effective cancer radiotherapy continues apace, with Telix Pharmaceuticals (ASX:TLX) today reporting “encouraging” preliminary results from its phase II study to treat recurrent high ...

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase ...